Autoimmune hepatitis is a chronic liver disease caused by an abnormal immune response against liver cells, leading to inflammation and liver damage. The disease affects primarily women and can occur at any age, but it is more common in middle-aged individuals. The goal of treatment for autoimmune hepatitis is to suppress the immune system and prevent further liver damage. The current standard of care for autoimmune hepatitis includes the use of immunosuppressive medications such as corticosteroids and azathioprine. These drugs are effective in inducing remission in most patients, but they can have significant side effects and may not be effective in all cases. As a result, there is a need for new and improved treatments for autoimmune hepatitis.
Autoimmune hepatitis (AIH) is a chronic liver disease that occurs when the body's immune system attacks liver cells, causing inflammation and damage. AIH can progress to cirrhosis and liver failure if left untreated. The exact cause of AIH is unknown, but it is believed to be triggered by a combination of genetic and environmental factors. AIH is a rare disease, with a prevalence of 10-40 cases per 100,000 individuals in North America and Europe. It is more common in women than men and can occur at any age, although it is most commonly diagnosed in individuals between the ages of 15 and 40. AIH is also more prevalent in certain ethnic groups, including individuals of Northern European and Middle Eastern descent.
Several drugs are currently in development for the treatment of autoimmune hepatitis. One promising drug is B-701, a monoclonal antibody that targets a specific protein on B cells, a type of immune cell that plays a role in autoimmune diseases. B-701 has shown promising results in early clinical trials, with a favorable safety profile and the potential to improve outcomes for patients with autoimmune hepatitis. Another drug in development is EYP001, a small molecule inhibitor of the Janus kinase (JAK) pathway. The JAK pathway is involved in immune cell signaling and has been implicated in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. EYP001 has shown promising results in preclinical studies and is currently in early-stage clinical trials for the treatment of autoimmune hepatitis.
Furthermore, in recent years, the autoimmune hepatitis (AIH) drug market has seen significant developments in the development of new treatments, including novel immunosuppressive agents and combination therapies. These treatments are increasing the options available to clinicians and improving patient outcomes. One example of a novel immunosuppressive agent is mycophenolate mofetil (MMF). MMF has been shown to be effective in inducing and maintaining remission in AIH patients who do not respond to or cannot tolerate traditional treatment with corticosteroids. It works by inhibiting the proliferation of lymphocytes and reducing the production of antibodies, which are the hallmarks of autoimmune disease.
Another combination therapy is the combination of MMF and corticosteroids. This therapy has been shown to be effective in inducing remission in AIH patients who do not respond to traditional treatment, and it may have fewer side effects than traditional treatment with corticosteroids alone. Overall, these developments in new treatments and combination therapies are improving the options available to clinicians and the outcomes for AIH patients. However, further research is needed to optimize these treatments and identify new targets for therapy in AIH.
 
New product launches to flourish in the market
There have been several new product launches in the AIH drug market in recent years: Imraldi (adalimumab): In October 2018, Samsung Bioepis launched Imraldi, a biosimilar version of Humira (adalimumab), for the treatment of various autoimmune diseases, including AIH; Maviret (glecaprevir/pibrentasvir): In August 2018, AbbVie launched Maviret, a combination therapy for the treatment of chronic hepatitis C, including in patients with AIH; Zeposia (ozanimod): In March 2020, Bristol-Myers Squibb launched Zeposia, a sphingosine 1-phosphate receptor modulator, for the treatment of relapsing forms of multiple sclerosis. While not specifically approved for AIH, it is being studied for its potential use in the disease; Lupkynis (voclosporin): In January 2021, Aurinia Pharmaceuticals launched Lupkynis, an oral calcineurin inhibitor, for the treatment of lupus nephritis. While not specifically approved for AIH, it is being studied for its potential use in the disease.
 
Segment Overview: 
By Drug Class: The autoimmune hepatitis drug market is divided into Oral antivirals and Immune modulators. Oral antivirals may be used as adjunctive therapy in some cases, such as when a patient with AIH also has a viral infection such as hepatitis B or C. In such cases, antivirals can be used to treat the viral infection and help prevent further liver damage. Examples of oral antivirals that may be used in combination with other medications for AIH treatment include: Entecavir (Baraclude), Tenofovir (Viread) and Sofosbuvir (Sovaldi). Moreover, immune modulators are a class of drugs used in the treatment of autoimmune hepatitis (AIH) to suppress the immune system and reduce inflammation in the liver. These drugs work by targeting specific components of the immune system involved in the autoimmune response, such as T-cells and B-cells.
 
By Distribution Channel: The autoimmune hepatitis drug market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Autoimmune hepatitis drugs are typically prescription medications that are used to treat autoimmune hepatitis, a chronic inflammatory liver disease. These drugs are typically available through hospital pharmacies, drug stores and retail pharmacies, and online providers. Hospital pharmacies are typically the primary source of these drugs for patients who are receiving treatment in a hospital setting. Drug stores and retail pharmacies, such as CVS and Walgreens, are also common providers of autoimmune hepatitis drugs for patients who are receiving treatment on an outpatient basis. Patients can obtain their prescriptions from their healthcare providers and then fill them at a local pharmacy.
 
In recent years, online providers have become increasingly popular as a source of prescription medications, including autoimmune hepatitis drugs. Online providers may offer the convenience of home delivery and the ability to order refills online. However, patients should exercise caution when ordering prescription medications online and ensure that they are purchasing from a reputable and licensed provider.
 
By Region: The Asia-Pacific autoimmune hepatitis drug market is one of the fastest-growing markets globally, driven by a combination of factors such as increasing incidence of autoimmune hepatitis, rising awareness about the disease, improving healthcare infrastructure, and growing government initiatives to provide better healthcare facilities. Some of the examples of autoimmune hepatitis drugs that are gaining traction in the region include: Prednisone and Azathioprine, which is widely used as a first-line treatment for autoimmune hepatitis. The drug combination is effective in controlling inflammation and preventing liver damage. In addition, Mycophenolate mofetil is an immunosuppressive drug and is gaining popularity in the region as a second-line treatment option for autoimmune hepatitis. Mycophenolate mofetil is effective in controlling inflammation and reducing the need for high-dose steroid therapy.
 
Furthermore, Tacrolimus drug is another immunosuppressive agent that is used to treat autoimmune hepatitis in the region. Tacrolimus is generally used as a salvage therapy for patients who do not respond to standard treatment. Budesonide is an alternative to prednisone and is effective in reducing inflammation in the liver. It is particularly useful for patients with mild to moderate autoimmune hepatitis. Overall, the Asia-Pacific autoimmune hepatitis drug market is expected to grow rapidly in the coming years, driven by increasing awareness and better treatment options for this chronic inflammatory liver disease.
 
Competitive analysis and profiles of the major players in the autoimmune hepatitis drug market, such as AbbVie Inc., Bristol Myers & Squibb, Cipla Ltd, Gilead Sciences, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Lupin, Merck & Co. Inc., Teva Pharmaceutical Industries Limited and Zydus Wellness Ltd are provided in the report. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the autoimmune hepatitis drug market.     

 Key Market Segments

• By Drug Class
  • Oral antivirals
  • Immune modulators
• By Distribution Channel
  • Hospital pharmacies
  • Drug stores & retail pharmacies
  • Online providers
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
    • Malaysia
    • Indonesia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • UAE
    • Argentina
    • Rest of LAMEA

 
Key Market Players

• Merck & Co. Inc.
• Cipla Ltd
• Lupin
• AbbVie Inc.
• F. Hoffmann-La Roche AG
• Gilead Sciences
• Bristol Myers & Squibb
• Teva Pharmaceutical Industries Limited
• Zydus Wellness Ltd
• GlaxoSmithKline plc

TABLE OF CONTENTS

• CHAPTER 1:    INTRODUCTION

  • 1.1.   Report description

  • 1.2.   Key benefits for stakeholders

  • 1.3.   Key market segments

  • 1.4.   Research methodology

  • • 1.4.1.   Primary research

    • 1.4.2.   Secondary research

    • 1.4.3.   Analyst tools and models

  CHAPTER 2:    EXECUTIVE SUMMARY

  • 2.1.   Key findings of the study

  • 2.2.   CXO perspective

  CHAPTER 3:    MARKET OVERVIEW

  • 3.1.   Market definition and scope

  • 3.2.   Key findings

  • • 3.2.1.   Top investment pockets

    • 3.2.2.   Top wining strategies

  • 3.3.   Porter’s five forces analysis

  • 3.4.   Top player positioning/Market share analysis

  • 3.5.   Market dynamics

  • • 3.5.1.   Drivers

    • 3.5.2.   Restraint

    • 3.5.3.   Opportunity

  • 3.6.   COVID-19 Impact Analysis

• CHAPTER 4 : AUTOIMMUNE HEPATITIS DRUG , BY DRUG CLASS

  • 4.1.   Overview

    • 4.1.1 Market size and forecast, by drug class

  • 4.2.   Oral antivirals

  • • 4.2.1. Key market trends, growth factors and opportunities

    • 4.2.2. Market size and forecast, by region

    • 4.2.3. Market share analysis, by country

  • 4.3.   Immune modulators

  • • 4.3.1. Key market trends, growth factors and opportunities

    • 4.3.2. Market size and forecast, by region

    • 4.3.3. Market share analysis, by country

• CHAPTER 5 : AUTOIMMUNE HEPATITIS DRUG , BY DISTRIBUTION CHANNEL

  • 5.1.   Overview

    • 5.1.1 Market size and forecast, by distribution channel

  • 5.2.   Hospital pharmacies

  • • 5.2.1. Key market trends, growth factors and opportunities

    • 5.2.2. Market size and forecast, by region

    • 5.2.3. Market share analysis, by country

  • 5.3.   Drug stores & retail pharmacies

  • • 5.3.1. Key market trends, growth factors and opportunities

    • 5.3.2. Market size and forecast, by region

    • 5.3.3. Market share analysis, by country

  • 5.4.   Online providers

  • • 5.4.1. Key market trends, growth factors and opportunities

    • 5.4.2. Market size and forecast, by region

    • 5.4.3. Market share analysis, by country

• CHAPTER 6 : AUTOIMMUNE HEPATITIS DRUG , BY REGIONS

  • 6.1.  Overview

  • 6.2.  NORTH AMERICA

    • 6.2.1. Key market trends, growth factors, and opportunities

    • 6.2.2. Market size and forecast, by drug class

    • 6.2.3. Market size and forecast, by distribution channel

    • 6.2.4. Market size and forecast, by country

    • 6.2.5. U.S.

      • 6.2.5.1. Key market trends, growth factors, and opportunities

      • 6.2.5.2 Market size and forecast, by drug class

      • 6.2.5.3 Market size and forecast, by distribution channel

    • 6.2.6. Canada

      • 6.2.6.1. Key market trends, growth factors, and opportunities

      • 6.2.6.2 Market size and forecast, by drug class

      • 6.2.6.3 Market size and forecast, by distribution channel

    • 6.2.7. Mexico

      • 6.2.7.1. Key market trends, growth factors, and opportunities

      • 6.2.7.2 Market size and forecast, by drug class

      • 6.2.7.3 Market size and forecast, by distribution channel

  • 6.3.  EUROPE

    • 6.3.1. Key market trends, growth factors, and opportunities

    • 6.3.2. Market size and forecast, by drug class

    • 6.3.3. Market size and forecast, by distribution channel

    • 6.3.4. Market size and forecast, by country

    • 6.3.5. France

      • 6.3.5.1. Key market trends, growth factors, and opportunities

      • 6.3.5.2 Market size and forecast, by drug class

      • 6.3.5.3 Market size and forecast, by distribution channel

    • 6.3.6. Germany

      • 6.3.6.1. Key market trends, growth factors, and opportunities

      • 6.3.6.2 Market size and forecast, by drug class

      • 6.3.6.3 Market size and forecast, by distribution channel

    • 6.3.7. Italy

      • 6.3.7.1. Key market trends, growth factors, and opportunities

      • 6.3.7.2 Market size and forecast, by drug class

      • 6.3.7.3 Market size and forecast, by distribution channel

    • 6.3.8. Spain

      • 6.3.8.1. Key market trends, growth factors, and opportunities

      • 6.3.8.2 Market size and forecast, by drug class

      • 6.3.8.3 Market size and forecast, by distribution channel

    • 6.3.9. UK

      • 6.3.9.1. Key market trends, growth factors, and opportunities

      • 6.3.9.2 Market size and forecast, by drug class

      • 6.3.9.3 Market size and forecast, by distribution channel

    • 6.3.10. Russia

      • 6.3.10.1. Key market trends, growth factors, and opportunities

      • 6.3.10.2 Market size and forecast, by drug class

      • 6.3.10.3 Market size and forecast, by distribution channel

    • 6.3.11. Rest of Europe

      • 6.3.11.1. Key market trends, growth factors, and opportunities

      • 6.3.11.2 Market size and forecast, by drug class

      • 6.3.11.3 Market size and forecast, by distribution channel

  • 6.4.  ASIA-PACIFIC

    • 6.4.1. Key market trends, growth factors, and opportunities

    • 6.4.2. Market size and forecast, by drug class

    • 6.4.3. Market size and forecast, by distribution channel

    • 6.4.4. Market size and forecast, by country

    • 6.4.5. China

      • 6.4.5.1. Key market trends, growth factors, and opportunities

      • 6.4.5.2 Market size and forecast, by drug class

      • 6.4.5.3 Market size and forecast, by distribution channel

    • 6.4.6. Japan

      • 6.4.6.1. Key market trends, growth factors, and opportunities

      • 6.4.6.2 Market size and forecast, by drug class

      • 6.4.6.3 Market size and forecast, by distribution channel

    • 6.4.7. India

      • 6.4.7.1. Key market trends, growth factors, and opportunities

      • 6.4.7.2 Market size and forecast, by drug class

      • 6.4.7.3 Market size and forecast, by distribution channel

    • 6.4.8. South Korea

      • 6.4.8.1. Key market trends, growth factors, and opportunities

      • 6.4.8.2 Market size and forecast, by drug class

      • 6.4.8.3 Market size and forecast, by distribution channel

    • 6.4.9. Australia

      • 6.4.9.1. Key market trends, growth factors, and opportunities

      • 6.4.9.2 Market size and forecast, by drug class

      • 6.4.9.3 Market size and forecast, by distribution channel

    • 6.4.10. Thailand

      • 6.4.10.1. Key market trends, growth factors, and opportunities

      • 6.4.10.2 Market size and forecast, by drug class

      • 6.4.10.3 Market size and forecast, by distribution channel

    • 6.4.11. Malaysia

      • 6.4.11.1. Key market trends, growth factors, and opportunities

      • 6.4.11.2 Market size and forecast, by drug class

      • 6.4.11.3 Market size and forecast, by distribution channel

    • 6.4.12. Indonesia

      • 6.4.12.1. Key market trends, growth factors, and opportunities

      • 6.4.12.2 Market size and forecast, by drug class

      • 6.4.12.3 Market size and forecast, by distribution channel

    • 6.4.13. Rest of Asia-Pacific

      • 6.4.13.1. Key market trends, growth factors, and opportunities

      • 6.4.13.2 Market size and forecast, by drug class

      • 6.4.13.3 Market size and forecast, by distribution channel

  • 6.5.  LAMEA

    • 6.5.1. Key market trends, growth factors, and opportunities

    • 6.5.2. Market size and forecast, by drug class

    • 6.5.3. Market size and forecast, by distribution channel

    • 6.5.4. Market size and forecast, by country

    • 6.5.5. Brazil

      • 6.5.5.1. Key market trends, growth factors, and opportunities

      • 6.5.5.2 Market size and forecast, by drug class

      • 6.5.5.3 Market size and forecast, by distribution channel

    • 6.5.6. South Africa

      • 6.5.6.1. Key market trends, growth factors, and opportunities

      • 6.5.6.2 Market size and forecast, by drug class

      • 6.5.6.3 Market size and forecast, by distribution channel

    • 6.5.7. Saudi Arabia

      • 6.5.7.1. Key market trends, growth factors, and opportunities

      • 6.5.7.2 Market size and forecast, by drug class

      • 6.5.7.3 Market size and forecast, by distribution channel

    • 6.5.8. UAE

      • 6.5.8.1. Key market trends, growth factors, and opportunities

      • 6.5.8.2 Market size and forecast, by drug class

      • 6.5.8.3 Market size and forecast, by distribution channel

    • 6.5.9. Argentina

      • 6.5.9.1. Key market trends, growth factors, and opportunities

      • 6.5.9.2 Market size and forecast, by drug class

      • 6.5.9.3 Market size and forecast, by distribution channel

    • 6.5.10. Rest of LAMEA

      • 6.5.10.1. Key market trends, growth factors, and opportunities

      • 6.5.10.2 Market size and forecast, by drug class

      • 6.5.10.3 Market size and forecast, by distribution channel

• CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction

  • 7.2. Top Winning Strategies

  • 7.3. Product Mapping Of Top 10 Player

  • 7.4. Competitive Dashboard

  • 7.5. Competitive Heatmap

  • 7.6. Top Player Positioning, 2022

• CHAPTER 8 : COMPANY PROFILES

• 8.1. ABBVIE INC.

• 8.1.1. Company overview

• 8.1.2. Business performance

• 8.1.3. Key strategic moves and developments

• 8.2. BRISTOL MYERS & SQUIBB

• 8.2.1. Company overview

• 8.2.2. Business performance

• 8.2.3. Key strategic moves and developments

• 8.3. CIPLA LTD

• 8.3.1. Company overview

• 8.3.2. Business performance

• 8.3.3. Key strategic moves and developments

• 8.4. GILEAD SCIENCES

• 8.4.1. Company overview

• 8.4.2. Business performance

• 8.4.3. Key strategic moves and developments

• 8.5. GLAXOSMITHKLINE PLC

• 8.5.1. Company overview

• 8.5.2. Business performance

• 8.5.3. Key strategic moves and developments

• 8.6. F. HOFFMANN-LA ROCHE AG

• 8.6.1. Company overview

• 8.6.2. Business performance

• 8.6.3. Key strategic moves and developments

• 8.7. LUPIN

• 8.7.1. Company overview

• 8.7.2. Business performance

• 8.7.3. Key strategic moves and developments

• 8.8. MERCK & CO. INC.

• 8.8.1. Company overview

• 8.8.2. Business performance

• 8.8.3. Key strategic moves and developments

• 8.9. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

• 8.9.1. Company overview

• 8.9.2. Business performance

• 8.9.3. Key strategic moves and developments

• 8.10. ZYDUS WELLNESS LTD

• 8.10.1. Company overview

• 8.10.2. Business performance

• 8.10.3. Key strategic moves and developments

• LIST OF TABLES

• TABLE 1. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 2. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR ORAL ANTIVIRALS, BY REGION, 2022-2032 ($MILLION)
• TABLE 3. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR ORAL ANTIVIRALS, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 4. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR IMMUNE MODULATORS, BY REGION, 2022-2032 ($MILLION)
• TABLE 5. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR IMMUNE MODULATORS, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 6. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 7. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
• TABLE 8. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR HOSPITAL PHARMACIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 9. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
• TABLE 10. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 11. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
• TABLE 12. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET FOR ONLINE PROVIDERS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 13. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET, BY REGION, 2022-2032 ($MILLION)
• TABLE 14. NORTH AMERICA AUTOIMMUNE HEPATITIS DRUG, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 15. NORTH AMERICA AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 16. NORTH AMERICA AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 17. MEXICO AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 18. MEXICO AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 19. EUROPE AUTOIMMUNE HEPATITIS DRUG, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 20. EUROPE AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 21. EUROPE AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 22. REST OF EUROPE AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 23. REST OF EUROPE AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 24. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DRUG, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 25. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 26. ASIA-PACIFIC AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 27. REST OF ASIA-PACIFIC AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 28. REST OF ASIA-PACIFIC AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 29. LAMEA AUTOIMMUNE HEPATITIS DRUG, BY COUNTRY, 2022-2032 ($MILLION)
• TABLE 30. LAMEA AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 31. LAMEA AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 32. REST OF LAMEA AUTOIMMUNE HEPATITIS DRUG, BY DRUG CLASS, 2022-2032 ($MILLION)
• TABLE 33. REST OF LAMEA AUTOIMMUNE HEPATITIS DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
• TABLE 34. ABBVIE INC.: KEY EXECUTIVES
• TABLE 35. ABBVIE INC.: COMPANY SNAPSHOT
• TABLE 36. ABBVIE INC.: OPERATING SEGMENTS
• TABLE 37. ABBVIE INC.: PRODUCT PORTFOLIO
• TABLE 38. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 39. BRISTOL MYERS AND SQUIBB: KEY EXECUTIVES
• TABLE 40. BRISTOL MYERS AND SQUIBB: COMPANY SNAPSHOT
• TABLE 41. BRISTOL MYERS AND SQUIBB: OPERATING SEGMENTS
• TABLE 42. BRISTOL MYERS AND SQUIBB: PRODUCT PORTFOLIO
• TABLE 43. BRISTOL MYERS AND SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 44. CIPLA LTD: KEY EXECUTIVES
• TABLE 45. CIPLA LTD: COMPANY SNAPSHOT
• TABLE 46. CIPLA LTD: OPERATING SEGMENTS
• TABLE 47. CIPLA LTD: PRODUCT PORTFOLIO
• TABLE 48. CIPLA LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 49. GILEAD SCIENCES: KEY EXECUTIVES
• TABLE 50. GILEAD SCIENCES: COMPANY SNAPSHOT
• TABLE 51. GILEAD SCIENCES: OPERATING SEGMENTS
• TABLE 52. GILEAD SCIENCES: PRODUCT PORTFOLIO
• TABLE 53. GILEAD SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 54. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
• TABLE 55. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
• TABLE 56. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
• TABLE 57. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
• TABLE 58. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 59. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
• TABLE 60. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
• TABLE 61. F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
• TABLE 62. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
• TABLE 63. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 64. LUPIN: KEY EXECUTIVES
• TABLE 65. LUPIN: COMPANY SNAPSHOT
• TABLE 66. LUPIN: OPERATING SEGMENTS
• TABLE 67. LUPIN: PRODUCT PORTFOLIO
• TABLE 68. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 69. MERCK AND CO. INC.: KEY EXECUTIVES
• TABLE 70. MERCK AND CO. INC.: COMPANY SNAPSHOT
• TABLE 71. MERCK AND CO. INC.: OPERATING SEGMENTS
• TABLE 72. MERCK AND CO. INC.: PRODUCT PORTFOLIO
• TABLE 73. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 74. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
• TABLE 75. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
• TABLE 76. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
• TABLE 77. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
• TABLE 78. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
• TABLE 79. ZYDUS WELLNESS LTD: KEY EXECUTIVES
• TABLE 80. ZYDUS WELLNESS LTD: COMPANY SNAPSHOT
• TABLE 81. ZYDUS WELLNESS LTD: OPERATING SEGMENTS
• TABLE 82. ZYDUS WELLNESS LTD: PRODUCT PORTFOLIO
• TABLE 83. ZYDUS WELLNESS LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

• LIST OF FIGURES

• FIGURE 1. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET SEGMENTATION
• FIGURE 2. GLOBAL AUTOIMMUNE HEPATITIS DRUG MARKET
• FIGURE 3. SEGMENTATION AUTOIMMUNE HEPATITIS DRUG MARKET
• FIGURE 4. TOP INVESTMENT POCKET IN AUTOIMMUNE HEPATITIS DRUG MARKET
• FIGURE 5. TOP WINNING STRATEGIES, 2020-2022*
• FIGURE 6. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*(%)
• FIGURE 7. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
• FIGURE 8. MODERATE BARGAINING POWER OF BUYERS
• FIGURE 9. MODERATE BARGAINING POWER OF SUPPLIERS
• FIGURE 10. MODERATE THREAT OF NEW ENTRANTS
• FIGURE 10. LOW THREAT OF SUBSTITUTION
• FIGURE 11. HIGH COMPETITIVE RIVALRY
• FIGURE 12. TOP PLAYER POSITIONING, 2022
• FIGURE 13. MARKET SHARE ANALYSIS, 2022
• FIGURE 14. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALAUTOIMMUNE HEPATITIS DRUG MARKET
• FIGURE 15. AUTOIMMUNE HEPATITIS DRUG MARKET SEGMENTATION, BY DRUG CLASS
• FIGURE 16. AUTOIMMUNE HEPATITIS DRUG MARKET FOR ORAL ANTIVIRALS, BY COUNTRY, 2022-2032 ($MILLION)
• FIGURE 17. AUTOIMMUNE HEPATITIS DRUG MARKET FOR IMMUNE MODULATORS, BY COUNTRY, 2022-2032 ($MILLION)
• FIGURE 18. AUTOIMMUNE HEPATITIS DRUG MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
• FIGURE 19. AUTOIMMUNE HEPATITIS DRUG MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
• FIGURE 20. AUTOIMMUNE HEPATITIS DRUG MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
• FIGURE 21. AUTOIMMUNE HEPATITIS DRUG MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2022-2032 ($MILLION)
• FIGURE 22. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
• FIGURE 23. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 24. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 25. BRISTOL MYERS AND SQUIBB: NET SALES, 2020-2022 ($MILLION)
• FIGURE 26. BRISTOL MYERS AND SQUIBB: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 27. BRISTOL MYERS AND SQUIBB: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 28. CIPLA LTD: NET SALES, 2020-2022 ($MILLION)
• FIGURE 29. CIPLA LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 30. CIPLA LTD: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 31. GILEAD SCIENCES: NET SALES, 2020-2022 ($MILLION)
• FIGURE 32. GILEAD SCIENCES: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 33. GILEAD SCIENCES: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 34. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
• FIGURE 35. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 36. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 37. F. HOFFMANN-LA ROCHE AG: NET SALES, 2020-2022 ($MILLION)
• FIGURE 38. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 39. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 40. LUPIN: NET SALES, 2020-2022 ($MILLION)
• FIGURE 41. LUPIN: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 42. LUPIN: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 43. MERCK AND CO. INC.: NET SALES, 2020-2022 ($MILLION)
• FIGURE 44. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 45. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 46. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2020-2022 ($MILLION)
• FIGURE 47. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 48. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
• FIGURE 49. ZYDUS WELLNESS LTD: NET SALES, 2020-2022 ($MILLION)
• FIGURE 50. ZYDUS WELLNESS LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
• FIGURE 51. ZYDUS WELLNESS LTD: REVENUE SHARE, BY REGION, 2032 (%)